Navigation Links
Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
Date:9/17/2012

currently in an international, randomized Phase 2b clinical trial (TRAVERSE) in patients with advanced primary liver cancer who have failed sorafenib therapy. In addition, JX-594 is being tested in the same patient population in combination with sorafenib. JX-594 is also in a Phase 1/2 clinical trials in patients with treatment-refractory colorectal cancer. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target and cause destruction of a variety of common solid tumor types and trigger a potent immune response. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through targeted viral replication, the ablation of the blood supply to tumors and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com. For studies evaluating JX-594 please visit www.clinicaltrials.gov.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
2. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
3. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
4. Mettler Toledo Presents In-depth Guidance to Comply with New USP Chapters 41 and 1251 on Balances Used for Quantitative Analysis in the Pharma QC Lab
5. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
6. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
7. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
8. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline
11. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... SANTA MONICA, Calif. , Oct. 24, 2014 ... medtech leaders over friendly robotic competition at the  ... Conference on October 29-30 th at ... The event will highlight local student built robots ... and Technology" (FIRST) competition.  FIRST students and mentors ...
(Date:10/25/2014)... Oct. 24, 2014   Metanome, Inc. , a ... services and data analysis, was the genomic sequencing provider ... Phase I/II clinical trial of SER 109, an Ecobiotic® ... Clostridium difficile infections (CDI). Metanome has ... R&D and clinical programs. Such genomic characterization has enabled ...
(Date:10/25/2014)... HILL, N.C. , Oct. 24, 2014 /PRNewswire/ ... teams can provide a company access to diverse ... emerging markets, and round-the clock business hours for ... overcoming difficult hurdles. According to ... team disappointments, such as seeing a project not ...
Breaking Medicine Technology:Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 2Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 3Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Work Around the Clock: Successfully Building & Managing Global Virtual Teams 2
... Amicus Therapeutics (Nasdaq: FOLD ) today announced ... No. 7,501,439, titled "Tartrate Salt of Isofagomine and Methods of ... isofagomine, the active ingredient in the Company,s investigational drug Plicera(TM) ... disease. The patent will expire in 2027. John ...
... CONFIRM SAFETY AND EFFICACY FOR ROOM TEMPERATURE STORAGENANTONG ... Bulletin Board: SNBP) is pleased to announce that ... skeletal muscle relaxant marketed as Kutai in China, ... multi-center Phase IV Clinical Study investigated the safety ...
Cached Medicine Technology:Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent 2Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent 3Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing 2Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing 3
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 More ... annual President’s Circle Reception on Monday at the home ... accomplishments and hear from guest speaker Dr. Winifred Lender ... worlds. , Dr. Lender, a Santa Barbara psychologist, author ... challenges and benefits of living in the digital age. ...
(Date:10/25/2014)... QueenBeeTickets.com has a variety of tickets for online ... Bob Seger & The Silver Bullet Band tickets for ... going on sale October 25 and are expected to ... the selection of tickets for Bob Seger & The ... is touring North America beginning next month, and he ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Interrupting blood supply to ... reduce the risks associated with the surgery, according to a ... stop the blood supply to the heart to be able ... the heart will reduce its ability to produce energy because ... flow to another large muscle, such as an arm or ...
(Date:10/25/2014)... Current osteoporosis screening guidelines and tools fail to ... osteoporosis-related fractures, a new study says. "If ... that help us accurately predict who will suffer ... these at-risk people for preventive measures," study author ... division of general internal medicine and health services ...
(Date:10/22/2014)... October 22, 2014 On October 22, ... featuring skin diseases both fictional and real. The ... a nonprofit organization committed to advocacy and philanthropy in ... will take the opportunity to impart truth and clarity ... , There are many misconceptions about Morgellons Disease ...
Breaking Medicine News(10 mins):Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... clinical trials on a new investigational drug being developed ... been successfully completed. Completion of the initial phase ... prepared by researchers at Cardiff University,s Welsh School of ... an approved medicine have significantly improved. Approximately ...
... N.C. Millions of patients with advanced disease in palliative ... easily. But a new study from Duke University Medical ... intervention, and among those who do benefit, it doesn,t make ... just plain old room air both offer equal benefit. ...
... Reporter , THURSDAY, Sept. 2 (HealthDay News) -- An ... two hours, making only one doctor visit necessary before ... advance against a disease that kills nearly 2 million ... "This is a very important discovery," said infectious disease ...
... and a little serendipity led a Northwestern University research team ... used for gas storage and food and medical technologies. And ... first known all-natural metal-organic frameworks (MOFs) that are simple to ... the Northwestern MOFs you can pop into your mouth and ...
... Stem cells might be thought of as trunks in the ... can turn into a dazzling variety other cellskidney, brain, heart ... the capacity to turn into virtually any cell type in ... of cell therapies, the conquering of age-old diseases or even ...
... September, 2010 - Elsevier announced today the publication of ... Andropause Society (EMAS) in the journal Maturitas ... post-reproductive health of women. The statements cover the ... epilepsy, endometriosis and premature ovarian failure. Each statement ...
Cached Medicine News:Health News:First clinical trials successfully completed on potent new hepatitis C drug 2Health News:Study challenges value of oxygen therapy in end-of-life care 2Health News:Study challenges value of oxygen therapy in end-of-life care 3Health News:Experimental TB Test Called Fast and Accurate 2Health News:Experimental TB Test Called Fast and Accurate 3Health News:Edible nanostructures 2Health News:Edible nanostructures 3Health News:Study finds that cancer-causing gene crucial in stem cell development 2Health News:Study finds that cancer-causing gene crucial in stem cell development 3Health News:EMAS publishes position statements about the post-reproductive health of women 2
1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride, 7.5% Glycerol....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Inoculum Broth with Calcium Chloride and Phytone....
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
Medicine Products: